SCHEDULE: Braeden Lichti and Northstrive Fund Exit Bluejay Position

Braeden Lichti and Northstrive Fund II LP have filed an exit notice confirming the sale of their entire stake in Bluejay Diagnostics, Inc.

Summary

• Braeden Lichti and Northstrive Fund II LP have disposed of all shares of Bluejay Diagnostics, Inc. common stock.
• As of June 2, 2026, the reporting persons hold zero shares and no longer beneficially own any interest in the issuer.
• This filing serves as the final amendment to the previously filed Schedule 13D, marking a complete exit from the investment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a standard regulatory disclosure of a completed divestment with no impact on the company's operational status.

Positives

• The filing provides full transparency regarding the complete divestment of the reporting persons' position.

Negatives

• The exit of a significant shareholder can sometimes be perceived as a lack of long-term confidence in the issuer's immediate prospects.

Risks

• Potential market volatility resulting from the complete liquidation of a previously disclosed significant position.

Future Outlook

Not applicable as the reporting persons have fully exited their position in the issuer.

Industry Context

StockSavvy.ai notes that the exit of institutional or significant individual investors from small-cap diagnostic companies is often a routine portfolio rebalancing move, though it warrants monitoring for any underlying shifts in company fundamentals.

Comparison to Industry Standards

• The filing follows standard SEC regulatory requirements for reporting the cessation of beneficial ownership above the 5% threshold.

Legal Proceedings

• None disclosed.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Shareholders should note the removal of this specific block of shares from the reporting persons' control.

Next Steps

• No further filings are required from these reporting persons regarding Bluejay Diagnostics, Inc.

Key Dates

Keywords

Bluejay Diagnostics, Schedule 13D, Divestment, Exit Filing, Braeden Lichti, Northstrive Fund